The evolving options in metastatic castration-sensitive prostate cancer

Area of Science:

• Oncology
• Urology
• Medical Treatments

Background:

• Metastatic castration-sensitive prostate cancer (mCSPC) treatment has evolved significantly.
• Established guidelines include androgen deprivation therapy (ADT) with docetaxel or abiraterone acetate, based on trials like CHAARTED and LATITUDE.

Purpose of the Study:

• To review recent advancements in mCSPC treatment.
• To compare novel therapeutic combinations and emerging evidence.
• To guide personalized treatment strategies for mCSPC patients.

Main Methods:

• Review of randomized controlled trials investigating new treatment combinations for mCSPC.
• Analysis of data from trials involving enzalutamide and apalutamide with ADT.
• Evaluation of emerging evidence for radiotherapy in metastatic prostate cancer.

Main Results:

• Recent trials demonstrate survival gains with enzalutamide plus ADT and apalutamide plus ADT in mCSPC.
• These combinations expand therapeutic options beyond established treatments.
• Emerging data suggests potential benefits of radiotherapy for the primary tumor in metastatic settings.

Conclusions:

• Novel androgen receptor inhibitors (enzalutamide, apalutamide) combined with ADT represent significant progress in mCSPC management.
• Distinguishing between these therapies is crucial for personalized patient care.
• Further research into radiotherapy's role may offer additional treatment avenues.